Compare Natera Inc. Common Stock (NTRA) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Direxion Daily S&P 500 Bull 3X Shares trades at $284.89 (market cap $7.36B). The key difference: Natera Inc. Common Stock is far larger — about 7.7× Direxion Daily S&P 500 Bull 3X Shares's market cap, and Natera Inc. Common Stock is more actively traded (1,131,157 versus 1,127,892). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Direxion Daily S&P 500 Bull 3X Shares for 33 Days on average.
| NTRA | SPXL | |
|---|---|---|
Market Cap | $57.03B | $7.36B |
Volume | 1,131,157 | 1,127,892 |
Sector | Health | Leveraged / Inverse |
52-Week High | $425.64 | $301.38 |
52-Week Low | $179.42 | $170.20 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SPXL trades at $297.37 with no daily change, maintaining a bullish technical stance supported by moving averages. The ETF shows neutral oscillator signals with RSI at 75.74 suggesting potential overbought conditions. Recent news highlights S&P 500 valuation concerns amid strong profit growth expectations of 35% for 2026, though projections slow to 15% for 2027 according to Wall Street analysts.
The ETF's outlook remains tied to S&P 500 performance, with seasonal patterns and earnings growth as key catalysts. Risks include market concentration in top holdings and geopolitical uncertainty. Analyst sentiment is mixed with technical indicators favoring upside while fundamental valuations warrant caution given projected earnings deceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
